Keywords: AM; Atrial cardiomyocyte; AP; Action potential; APA; Action potential amplitude; APD; Action potential duration; CICR; Ca2+-induced Ca2+ release; CK; Creatine kinase; CM; Cardiomyocyte; cTNI; Troponin I, cardiac type; cTnT; Cardiac troponin T; CÂ ÃÂ 40;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CDI; Cellular Dynamics International; DETECTIVE; Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems; FCCP; carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; hiPSC-CMs; human induced pluripotent stem cell-derived car
Keywords: APD90; action potential duration at 90% repolarization; BDM; 2,3-butanedione monoxime; BTS; N-benzyl-p-toluene sulphonamide; Cav1.2; calcium channel produced from the CACNA1C gene; cTnI; cardiac troponin I; C-E curve; concentration-effect curve; Cx43; con
Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report
Keywords: Safety pharmacology; Cardiotoxicity; Human-induced pluripotent stem cell-derived cardiomyocytes; Multi-electrode array technology; APD; action potential duration; APC; automated patch clamp; CiPA; Comprehensive in vitro Proarrhythmia Assay; CSRC; Cardiac
In silico assessment of the effects of various compounds in MEA/hiPSC-CM assays: Modeling and numerical simulations
Keywords: Cardiac electrophysiology; MEA; Field potential; Drug modeling; hIPSC-CMs;
Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytes
Keywords: Myotonic Dystrophy type 1 (DM1); Human induced pluripotent stem cells; Cardiomyocytes; Electrophysiological analysis; Antiarrhytmic drugs; ACTN2; sarcomeric alpha actinin; AFM; atomic force microscopy; AP; action potential; APD; action potential duration;
Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes
Keywords: Arrhythmia; EAD; CardioExcyte 96; Cardiomyocytes; CiPA; Contractility; Extracellular field potential; hiPSC; Impedance; Safety pharmacology; AXG; Cor.4U®, hiPSC-CMs, Ncardia; BrCoV; Beat rate (beat period) coefficient of variation; CDI; iCell Cardiomyocy
An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities
Keywords: Cardiotoxicity; Impedance; Cardiomyocytes; iPSC; In vitro; Drug discovery; CiPA; comprehensive in vitro proarrhythmia assay; hIPSC-CMs; human induced pluripotent stem cell cardiomyocytes; HDAC; histone deacetylase inhibitors;
The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study
Keywords: AP; cardiac action potential; CiPA; comprehensive in vitro proarrhythmia assay; CSRC; Cardiac Safety Research Consortium; Cmax; maximal plasma concentration; CTWG; clinical translational working group; DRest; rate-normalized Tpeak â Tend = Tpe inter
Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation
Keywords: Comprehensive in vitro Proarrhythmia Assay (CiPA); Field potential data sampling and analysis; Induced pluripotent cell cardiomyocytes (hiPSC-CMs); Multi electrode array (MEA); Patch clamp technologies; Pending issues and solutions; Validation; Voltage se